APA引文

Nash, P., Coates, L., Kivitz, A., Mease, P., Gladman, D., Covarrubias-Cobos, J., . . . Kanik, K. (2018). Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: Data from the third interim analysis of opal balance, an open-label, long-term extension study. BMJ Publishing Group Limited.

芝加哥风格引文

Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of Opal Balance, an Open-label, Long-term Extension Study. BMJ Publishing Group Limited, 2018.

MLA引文

Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of Opal Balance, an Open-label, Long-term Extension Study. BMJ Publishing Group Limited, 2018.

警告:这些引文格式不一定是100%准确.